Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

PHASE4CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Invasive Candidiasis
Interventions
DRUG

Caspofungin

50 mg IV daily

DRUG

Normal Saline

100 cc IV daily

Trial Locations (12)

19104

University of Pennsylvania, Philadelphia

20010

Washington Hospital Center, Washington D.C.

29425

University of Southern California, Los Angeles

Medical Center of South Carolina, Charleston

35124

University of Alabama at Birmingham, Birmingham

43210

The Ohio State University, Columbus

48201

Harper University Hospital/ Wayne State, Detroit

48202

Henry Ford Hospital, Detroit

59802

St. Patrick's Hospital, Missoula

70112

Tulane University, New Orleans

80262

University of Colorado, Denver

08103

Cooper University Hospital, Camden

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Mycoses Study Group

NETWORK

NCT00520234 - Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) | Biotech Hunter | Biotech Hunter